Psoriasis is a common, immune-mediated, inflammatory disease mainly involving the skin and joints, that is genetically determined, strongly influenced by epigenetic mechanisms, and possibly triggered by environmental factors [1, 2].

Pathogenesis of psoriasis is extremely complex and fascinating: the studies on its main clinical subtypes, but also of its stages and corresponding histopathological features, have recently pointed out the involvement of autoinflammation, that is to say, a state of sterile inflammation, not mediated by circulating autoantibodies and autoreactive T cells [3, 4].

The clinical development of early lesions in psoriasis would be linked to periodic waves of autoinflammation, represented by burst of neutrophils and cytokines related to the interleukin-1 (IL-1) family, such as IL-1α, IL-1β, and IL-36, capable to initiate the disease [3].

Initiating events of the disease arise from a complex interplay between genetic and environmental factors (e.g., drugs, stress, smoking, trauma, microorganisms). In more detail, in genetically predisposed individuals, in these initial phases of the disease, cells from the innate immune system are activated by the above triggers, most notably via effectors of the innate immunity like the Toll-like receptors, and accumulate in the skin and in the other affected organs.

Keratinocytes are also activated, thus becoming in turn immune system cells, and release a number of chemokines further recruiting neutrophils and amplifying the inflammatory network.

Indeed, from a histopathological point of view, during the early stages of the disease as well as in its recurrent pustular flares, an infiltrate of cells of the innate immunity predominates in skin lesions, while cells from adaptive immunity like T lymphocytes are rare.

This first flare is rapidly followed by an accumulation in the lesional skin of T-helper (Th) 17 cells that produce proinflammatory cytokines such as IL-17 and IL-22 crosstalking with the IL-12/IL-23 axis. The clinical background of this phase is represented by papulo-pustulous lesions of psoriasis.

In the late stages of the disease, clinically characterized by plaque psoriasis, the inflammatory process is shifted to a classical Th1 cell-mediated immune response, with predominance of Th1 cell-related cytokines like tumor necrosis factor (TNF)-α and interferon (IFN)-γ [3].

Thus, in its initial events, psoriasis seems to reproduce exactly the pathogenetic model of classic autoinflammatory diseases, such as pyogenic arthritis, acne, and pyoderma gangrenosum (PAPA) syndrome, and neutrophilic dermatoses, such as idiopathic pyoderma gangrenosum, which are due to mutations of genes regulating the innate immunity and share with psoriasis the same cascade of cytokine release and cell activation [4-7].

As well, the link between psoriasis and different autoinflammatory conditions is also given from the clinical ground, as the occurrence of a severe erythrodermic and pustular presentation of psoriasis is present in several syndromes such as Deficiency of IL-1 Receptor Antagonist (DIRA) and Deficiency of IL-36 Receptor Antagonist (DITRA) [8, 9].

The aforementioned physiopathological model may support the view on psoriasis as a paradigm of skin disease with systemic involvement and hallmarked by an important autoinflammatory component.

A comprehensive knowledge of the complex interplay among the genetic/epigenetic factors and immunological mechanisms of autoinflammation should contribute to the development of novel targeted therapeutic strategies.

The authors have no conflicts of interest to declare.

Deng Y, Chang C, Lu Q: The inflammatory response in psoriasis: a comprehensive review. Clin Rev Allergy Immunol 2016; 50: 377–389.
Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009; 361: 496–509.
Christophers E, Metzler G, Röcken M: Bimodal immune activation in psoriasis. Br J Dermatol 2014; 170: 59–65.
Kastner DL, Aksentijevich I, Goldbach-Mansky R: Autoinflammatory disease reloaded: a clinical perspective. Cell 2010; 140: 784–790.
Marzano AV, Fanoni D, Antiga E, et al: Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome. Clin Exp Immunol 2014; 178: 48–56.
Marzano AV, Borghi A, Meroni PL, et al: Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol 2016; 175: 882–891.
Marzano AV, Damiani G, Ceccherini I, et al: Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol 2017; 176: 1588–1598.
Aksentijevich I, Masters SL, Ferguson PJ, et al: An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360: 2426–2437.
Marrakchi S, Guigue P, Renshaw BR, et al: Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620–628.
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.